绿康生化(002868) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 160,395,845.10, representing a 60.09% increase compared to CNY 100,190,694.85 in the same period last year[5]. - The net loss attributable to shareholders was CNY -31,342,797.54, a significant decline of 208.94% from CNY -10,145,375.67 in the previous year[5]. - The total operating revenue for Q1 2024 was CNY 160,395,845.10, an increase of 60.2% compared to CNY 100,190,694.85 in the same period last year[17]. - The net loss for Q1 2024 was CNY 31,573,220.52, compared to a net loss of CNY 10,416,863.97 in Q1 2023, representing an increase in loss of 202.5%[19]. - The company's gross profit margin decreased significantly, with gross profit for Q1 2024 at CNY -28,071,091.12, compared to CNY -10,976,905.22 in Q1 2023[19]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 75.38%, reaching CNY -15,243,576.62, compared to CNY -61,917,676.50 in the prior year[5]. - Total cash inflow from operating activities was 146,288,322.70 CNY, compared to 150,240,392.34 CNY in the previous year, reflecting a decrease of approximately 2.3%[21]. - Cash outflow from operating activities decreased to 161,531,899.32 CNY from 212,158,068.84 CNY, marking a reduction of about 23.9%[21]. - The ending balance of cash and cash equivalents was 68,380,217.19 CNY, compared to 42,933,481.60 CNY at the end of Q1 2023, indicating an increase of about 59.5%[22]. - The company received 6,249,871.39 CNY in tax refunds, down from 10,920,206.35 CNY in the previous year[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,953,475,326.13, a slight decrease of 0.59% from CNY 1,965,009,357.76 at the end of the previous year[5]. - The total liabilities increased to CNY 1,569,477,589.56 in Q1 2024, compared to CNY 1,550,898,558.00 in Q1 2023, reflecting a growth of 1.6%[16]. - The company's equity attributable to shareholders decreased to CNY 381,297,608.33 in Q1 2024 from CNY 411,287,522.61 in Q1 2023, a decline of 7.3%[16]. Operational Metrics - The company reported a significant increase in accounts receivable, which rose by 38.10% to CNY 118,849,696.89 due to increased sales of gel films[7]. - The company's management expenses increased by 73.89% to CNY 12,219,131.83, attributed to the integration of gel film subsidiary expenses[7]. - The financial expenses surged by 141.84% to CNY 16,270,060.42, primarily due to increased financing and interest expenses on project loans[7]. - Accounts receivable increased from 86,059,203.01 RMB to 118,849,696.89 RMB, representing a growth of about 38.2%[14]. - Inventory rose from 201,894,404.60 RMB to 210,229,326.59 RMB, an increase of approximately 4.6%[14]. - Fixed assets increased from 703,254,518.77 RMB to 909,638,726.12 RMB, reflecting a growth of about 29.3%[14]. Future Plans and Developments - The company plans to continue expanding its product offerings and market presence, focusing on the development of new technologies and products[5]. - The company plans to sell certain fixed assets and land use rights for 67.5 million RMB to a related party, Fujian Putan Thermal Energy Co., Ltd.[12]. - The company has not disclosed any new product or technology developments in the current report[11]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,643[10]. - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., holds 30.43% of shares, totaling 47,291,400 shares[10]. - There are no changes in the top 10 shareholders due to margin trading activities[11]. - The company has not identified any related party relationships among the other shareholders[11].